Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The anti-HCV antibody (C100-3) is present in the serum of 70-90% of patients that are carriers of posttransfusion non-A non-B hepatitis. This marker appears to be associated with a viral replication and infectiousness state. Since 1st August 1990 the Swiss Red Cross Transfusion Service has operated a systematic search for anti-HCV antibodies for every blood donation. The aim of the study was to establish the prevalence of anti-HCV antibodies in a donor population, look for the risk factors in the anti-HCV positive group, look for biological symptoms and signs of chronic hepatitis, and compare the data with that from an anti-HCV negative control group. From August to March 1991, 20,373 donors were tested by EIA (Ortho). The presence of anti-HCV antibody was confirmed by a neutralization test (Abbott). The donors in which both tests were positive formed the group studied (55 subjects). Their data was compared with that of a control group of anti-HCV negative donors. The prevalence of anti-HCV antibody in the group of 20,373 donors was 0.29%. Possible parenteral exposure to hepatitis C virus was found in 47% of anti-HCV positive subjects (30% blood transfusion, 9% i.v. drug addiction, 8% tattooing). 42% of the anti-HCV positive donors had no risk factor presently known for hepatitis C. 27% of anti-HCV positive donors had elevated transaminase levels. Until more effective screening tests are introduced it appears necessary to stress the previous history of future blood donors in order to search for hepatitis C risk factors.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Prevalence of anti-HCV (C100-3) antibodies in 20.373 blood donors]. 141 11

We evaluated the prevalence of hepatitis in our hemodialysed population (65 patients, 37 M and 28 F). Screening for A and B hepatitis was tested with the RIA method and research of the anti-HCV with the immunoenzymatic method (Ortho HCV ELISA test of 2nd generation). 15 patients (23.07%) were anti-HCV positive (anti-HCV+); 23 (35.38%) showed positivity for 1 or more markers of B hepatitis (HBV+). A meaningful greater prevalence of B virus infections in anti-HCV+ patients (86.66%), compared to negatives, (20.00%) resulted. All non-A, non-B hepatitides are anti-HCV+. The dialytic treatment of the anti-HCV+ patients was meaningfully longer than in the negatives (p less than 0.05). The prevalence of the seropositive patients to B and C virus is not correlated to the number of transfusions, while it is to the number of surgical operations carried out in the predialytic period. This information suggests common pathogenetic mechanisms between the 2 forms of hepatitis and increased probability to find anti-HCV+ with a longer dialytic treatment.
 ...
PMID:Prevalence of hepatitides in our hemodialyzed population. 150 28

Stored sera from 28 patients with inherited coagulation disorders who had developed non-A non-B hepatitis (NANBH) following a first exposure to clotting factor concentrates and 15 similar, but unmatched, patients who had received blood products but had normal transaminases on sequential testing were tested using the Ortho enzyme-linked immunosorbent assay (ELISA) anti-HCV assay. Twenty-seven of the 28 patients with NANBH were anti-HCV positive after exposure. In 10 of those in whom dates of first exposure and seroconversion were well-defined, the median time interval to NANBH was 4 weeks (range 1-7) and to anti-HCV seroconversion was 11 weeks (range 7.5-14.5). None of the 15 patients without NANBH developed anti-HCV. This first generation Ortho ELISA anti-HCV assay showed 96% sensitivity and 100% specificity and has potential use as an adjunct in the surveillance of new clotting factor products.
 ...
PMID:Hepatitis C antibody assay in a longitudinal study of haemophiliacs. 165 56

In this symposium, the speakers have discussed the progress of the current diagnostic methods available for the diagnosis of viral hepatitis type C, and the accuracy and reproducibility at hand now, or which should be attained in the near future. Since the first appearance of ELISA (Ortho) and RIA (Dainabot) kit, the screening of infected blood with HCV from donors has been very successful. Posttransfusion hepatitis following infected blood transfusion has clearly decreased. The carrier rate of HCV in the Ehime prefecture is reported to be 1.85% in males and 1.25% in females. Diagnostic methods of the second generation such as ELISA and RIBA using C200 and C22 (core) protein as antigens yield 92.6 to 100% positive results in a diagnosis of NANB hepatitis following anti-hemophilic sera injection or hemodialysis. Detection of HCV RNA by RT-PCR procedure promised accurate diagnosis. Using such diagnostic methods, the majority of the patients with NANB chronic hepatitis were diagnosed as having CH type C. IgM anti-C 100-3 antibody was not useful for early diagnosis of patients infected with HCV, but the titer was useful for determining the therapeutic response of patients on INF therapy. The route of infection was concluded to be mostly horizontal rather than vertical (maternal-child), though a few cases were present suggestive of maternal transmission. Interferon therapy against patients with CH type C was effective in CAH 2A, but only a poor response was observed in patients with CAH 2B.
 ...
PMID:[Symposium: Current evaluation of diagnostic methods on viral hepatitis type C and consequent clinical features]. 165 58

A specific ELISA test (KCL-163) for detecting anti-hepatitis C virus antibody (anti-HCV) has been developed (Kaketsuken). Using the KCL-163, 183 serum samples obtained from patients with non-A, non-B hepatitis (NANBH) were examined. We also tested and compared results with Ortho HCV ELISA (C100) and C825 ELISA. Of these 183 samples, 139 (76%), 121 (66%), and 88 (48%) were positive with KCL-163, C100 and C825, respectively. These results showed that there were patients with NANBH caused by HCV who were seronegative in C100 ELISA. KCL-163 ELISA is applicable for the diagnosis of HCV infection in these patients.
 ...
PMID:Evaluation of the KCL-163 ELISA test for detecting antibodies against hepatitis C virus in patients with non-A, non-B chronic hepatitis. 165 62

The prevalence of hepatitis C virus infection in hemodialysis patients in Japan was examined using sera from 418 patients from six dialysis units in 1989. The authors made use of an enzyme-linked immunosorbent assay (Ortho Diagnostics). Antibody to hepatitis C virus (anti-HCV) was detected in 127 patients (30.4%), the frequency varying from 20.0% to 34.9% in different units. The mean prevalence of anti-HCV was 20 times higher than that in blood donors. Anti-HCV positivity was not associated with antibody to hepatitis B core antigen, which was not a surrogate marker for non-A, non-B hepatitis agents in this study. Another striking finding of this study was that 84.3% of the anti-HCV-positive patients had normal liver function. Anti-HCV positivity correlated positively with the number of blood transfusions and increased with the duration of hemodialysis; however, it was 22.1% even in 113 patients never given blood transfusion. Acquisition of hepatitis C virus by dialysis patients is, therefore, not only through blood transfusions but also because of hepatitis C virus present within the unit itself. Liver dysfunction in the anti-HCV-positive patients was rare.
 ...
PMID:Prevalence of antibody to hepatitis C virus in hemodialysis patients. 165 84

In March 1989, ultrasonography revealed a hepatic mass in a 40 year old nulliparous woman who was then referred to the University of Southern California--Los Angeles (UCLA) Liver Unit. She exhibited no symptoms of a liver condition. From 19-28 years old, she took the combined oral contraceptive (OC) Ovulen 21 for irregular menses. After a brief period of taking Ortho Novum 1/80, she took Demulen 1/35-24 between ages 28-34. Her physician diagnoses endometriosis at 34. He stopped OC therapy and prescribed the progestin Norlutate. She had no history of hepatitis, toxin exposure, and previous liver disease. Further no one in her family had had liver disease or neoplasms. Computer tomography identified a 6.5 cm x 3.5 cm mass in the right lobe of the liver which matched a cold defect on a liver scan using technetium Tc 99m sulfur colloid. The mass selectively took up gallium. Arteriography revealed the mass to be a vascular tumor, but it did not exhibit a typical vascular pattern of an adenoma or the neovascularity of hepatocellular carcinoma. Physicians at UCLA used peritoneoscopy to take percutaneous needle biopsies of the right lobe which confirmed a hepatic adenoma. they then removed the right lobe of the liver. The remaining part of the liver was normal. Histologic examinations of the removed section showed features of a well differentiated hepatocellular carcinoma. Further tumor cells had invaded normal hepatic parenchyma. The physicians believed that hepatic adenoma was in the process of transforming into hepatocellular carcinoma in this patient. They thought that long term OC use, and possibly long term progestin use, may have contributed to the formation of the liver neoplasms. They emphasized the need for a pilot study to develop guidelines on surveillance ultrasonography of women taking OCs over a long period.
 ...
PMID:Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. 166 98

The nucleic acid sequence of the putative 5'-untranslated (5PUT) region of hepatitis C virus (HCV), determined for samples obtained from a variety of geographic origins, was found to be over 98% conserved among all isolates. On the basis of this signature sequence for HCV, a viral RNA assay was developed by using cDNA synthesis with reverse transcriptase, followed by polymerase chain reaction (PCR). The new assay was compared with the Ortho-Chiron C100-3 HCV enzyme-linked immunosorbent assay to research radioimmunoassays for antibodies to the C33c and C22 HCV antigens and to the first reported set of HCV PCR primers designed from the NS3 domain. Plasma samples from 16 Japanese patients with non-A, non-B hepatitis (NANBH) and 16 immunoassay-positive blood donors from the United States were investigated. The 5PUT PCR primers were found to be superior to the NS3 primers in sensitivity and specificity (15 of 25 versus 3 of 25 of the C100 enzyme-linked immunosorbent assay-positive samples, respectively). Samples from two C100-negative patients with acute NANBH were found to react with the 5PUT primers but not with the NS3 primers. Also, two of three patients with chronic NANBH converted from reverse transcriptase PCR positive to negative after interferon treatment. Although the clinical significance of the presence or absence of HCV RNA in samples from patients is not fully understood, the use of probes and primers from the 5PUT region (as opposed to primers from other segments) should not lead to false-negative results due to nucleic acid sequence variations in viral isolates.
 ...
PMID:Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. 166 10

A comparison between recombinant immunoblot assay hepatitis C virus (HCV) first generation (RIBA-1) and second generation (RIBA-2) was made on 732 blood donors reactive by anti-HCV ELISA (Ortho Diagnostics System) by the Hepatitis Study Group of the French Society of Blood Transfusion. RIBA-2 results were correlated with ELISA ratio and ALT levels. The number of both reactive and nonreactive samples was higher with RIBA-2 than with RIBA-1, 252 (34%) compared to 224 (31%) for reactive samples, and 404 (55%) compared to 307 (42%) for nonreactive samples. C 22-3 and C 33-c reactivities were observed in 96 and 91% of the reactive samples, respectively. A total of 76 samples (11%) remained indeterminate by RIBA-2, 84% of them reacting only on C 100-3 antigen. A clear relationship between RIBA-2 results and both ELISA ratio and alanine aminotransferase (ALT) levels was demonstrated: 20% of samples with normal ALT level and 10% of samples with low ELISA ratio were reactive when 91% of samples with ALT greater than 2N and 69% of samples with high ELISA ratio were reactive. The totality of the 57 samples with both ALT greater than 2N and high ELISA ratio were reactive and 93% of samples with normal ALT level and low ELISA ratio were nonreactive.
 ...
PMID:Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA. The Hepatitis Study Group of the French Society of Blood Transfusion. 166 33

Since November 1989, Japanese Red Cross blood centres throughout the country have screened donors for hepatitis C virus (HCV) with an Ortho enzyme-linked immunosorbent assay for antibody to the C100-3 viral peptide. Simultaneously, the centres started to screen for units with high-titre (greater than or equal to 2(6)) antibody to hepatitis B virus core antigen (HBcAb) in the absence of hepatitis B virus surface antigen and antibody. To test the effectiveness of this policy, the incidence of post-transfusion non-A, non-B hepatitis (PTNANBH) and post-transfusion hepatitis B (PTHB) after screening had been introduced (November, 1989, to December, 1990, inclusive) was compared with the incidence before screening (January, 1988, to October, 1989, inclusive). Incidence of PTNANBH in patients who had received 1-10 unit transfusions was 4.9% (58/1189) before screening vs 1.9% (15/784) afterwards. Incidence in those who had 11-20 unit transfusions was 16.3% (64/392) vs 3.3% (4/124). Incidence of PTHB was 0.25% (4/1597) before screening; no cases have been detected subsequently. These results show the effectiveness of the first-generation anti-HCV test and indicate the value of screening for high-titre HBcAb in addition to HBV surface antigen testing in HBV endemic areas.
 ...
PMID:Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. 168 56


<< Previous 1 2 3 4 5 6 7 Next >>